Table 3.
Factors associated with the presence of SARS-CoV-2 neutralizing antibodies (n = 412).
|
Model I Crude OR [95% CI] |
Model II Adjusted OR [95% CI] |
|
|---|---|---|
| Disease course | ||
| Asymptomatic/Mild | 1.0 | 1.0 |
| Moderate/Severe | 1.96 [1.18 – 2.27] | 2.07 [1.23–3.47] |
| Comorbidity | ||
| Yes | 1.0 | 1.0 |
| No | 1.39 [0.85 – 2.28] | 1.34 [0.79–2.27] |
| Time since positive RT-PCR | ||
| 0–59 days | 1.0 | |
| 60–119 days | 0.39 [0.22–0.70] | 0.35 [0.14–0.63] |
| 120 days and more | 0.15 [0.08–0.31] | 0.14 [0.07–028] |
| Sex | ||
| Male | 1.0 | |
| Female | 0.94 [0.58–1.52] | |
| Age group | ||
| 16–29 years | 1.0 | |
| 30–49 years | 1.02 [0.55–1.89] | |
| 50–69 years | 0.93 [0.53–1.78] | |
| 70 years and older | 2.56 [0.84–10.11] |
1.0 = reference category; OR, Odd Ratio; CI, Confidential Interval. This table presents the unadjusted (Model I) and the age and sex-adjusted odds ratio (OR) (Model II) of having neutralizing antibodies (Yes/No) by participant characteristics. The odds ratio was calculated to describe the factors of different groups in positive neutralizing antibody assays compared with negative neutralizing antibody assays.